Quick Answer
Benitec Biopharma Inc. reported R&D Expense of $18.33 million for fiscal year 2025.
Benitec Biopharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $18.33M | +17.4% |
| 2024 | $15.61M | +22.2% |
| 2023 | $12.77M | +13.3% |
| 2022 | $11.27M | +60.6% |
| 2021 | $7.02M | +133.9% |
| 2020 | $3.00M | -34.3% |
| 2019 | $4.57M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $5.83M | +8.3% | +73.1% |
| September 30, 2025 | $3.37M | -6.0% | -43.6% |
| March 31, 2025 | $5.98M | +133.0% | +11.0% |
| December 31, 2024 | $5.38M | +5.5% | +50.2% |
| September 30, 2024 | $3.58M | -19.1% | +39.7% |
| March 31, 2024 | $2.57M | -19.0% | -49.7% |
| December 31, 2023 | $5.10M | +35.7% | +15.2% |
| September 30, 2023 | $4.43M | +66.5% | +39.8% |
- Benitec Biopharma Inc. showed an increase of +17.4% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Benitec Biopharma Inc.’s r&d expense has grown by 301.4% (from $4.57 million to $18.33 million).
- The most recent figure is from Benitec Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: